Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

University of Toronto

$210,000.00

Next-Generation CRISPR Tools for High Precision Diagnostics and Genetic Engineering

EF 2024-25

Résumé
CRISPR, a technology that enables precise and targeted modification of DNA and RNA in living organisms, has revolutionized gene editing and diagnostics. It uses a guide RNA molecule to direct the CRISPR protein to a specific DNA/RNA sequence for targeted gene modification. However, its reliance on specific DNA sequences called protospacer adjacent motifs (PAMs) limits its use, especially when targeting specific areas in the gene. Currently, the dependence on the PAM has prevented genetic modification at the exact location of interest. My proposal will leverage a new platform, RNA/DNA Affinity Precision Innovative Diagnostics (RAPID), a PAM-free CRISPR technique, for direct gene targeting towards modification, which will drive rapid screening, designs, and accelerate drug discovery. will use RAPID to: 1.Improve the ability to detect blood infection (sepsis): we will develop methods for profiling genetic markers of infection to quickly and accurately diagnose sepsis. Using CRISPR's new capabilities, RAPID will enable point-of-care detection for timely and targeted treatment, improving patient outcomes and reducing healthcare costs. 2.Improve avian influenza detection in the "field": create easy-to-use sensors for detecting avian flu. This will enhance local and global health security, including pandemic readiness with a durable diagnostic tool. 3.Sickle cell anemia gene therapy: adapt RAPID for gene editing to treat sickle cell disease patients. This approach aims to edit the genetic mutation causing the disease precisely, offering a revolutionary treatment and cure that will give hope to millions affected by this genetic disorder. In conclusion, the RAPID platform's ability will represent a major advance in synthetic Biology. Through the CIHR fellowship, I will develop RAPID for the pathogens highlighted above, as well as adapt the technology for resolving genetic disorders.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
513801
Name
IWE Idorenyin A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Next-Generation CRISPR Tools for High Precision Diagnostics and Genetic Engineering
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$210,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Avian Influenza H5n1; Crispr; Diagnostics; Dna/Rna Crispr-Cas Sensor; Gene Editing; Gene Therapy; Multiplexing; Pam-Free Diagnostics And Editing; Pandemic Readiness; Sickle Cell Disease
Abstract
CRISPR, a technology that enables precise and targeted modification of DNA and RNA in living organisms, has revolutionized gene editing and diagnostics. It uses a guide RNA molecule to direct the CRISPR protein to a specific DNA/RNA sequence for targeted gene modification. However, its reliance on specific DNA sequences called protospacer adjacent motifs (PAMs) limits its use, especially when targeting specific areas in the gene. Currently, the dependence on the PAM has prevented genetic modification at the exact location of interest. My proposal will leverage a new platform, RNA/DNA Affinity Precision Innovative Diagnostics (RAPID), a PAM-free CRISPR technique, for direct gene targeting towards modification, which will drive rapid screening, designs, and accelerate drug discovery. will use RAPID to: 1.Improve the ability to detect blood infection (sepsis): we will develop methods for profiling genetic markers of infection to quickly and accurately diagnose sepsis. Using CRISPR's new capabilities, RAPID will enable point-of-care detection for timely and targeted treatment, improving patient outcomes and reducing healthcare costs. 2.Improve avian influenza detection in the "field": create easy-to-use sensors for detecting avian flu. This will enhance local and global health security, including pandemic readiness with a durable diagnostic tool. 3.Sickle cell anemia gene therapy: adapt RAPID for gene editing to treat sickle cell disease patients. This approach aims to edit the genetic mutation causing the disease precisely, offering a revolutionary treatment and cure that will give hope to millions affected by this genetic disorder. In conclusion, the RAPID platform's ability will represent a major advance in synthetic Biology. Through the CIHR fellowship, I will develop RAPID for the pathogens highlighted above, as well as adapt the technology for resolving genetic disorders.
Competitiondate
202410
Approvedterm2
3 yrs 0 mth
Pinamesdelim
IWE, Idorenyin A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $210,000~ $0~